| Hazard Information | Back Directory | [Uses]
PKI-166 hydrochloride is a potent, selective and orally active EGFR tyrosine kinase inhibitor, with an IC50 of 0.7 nM[1]. | [Biological Activity]
PKI-166 hydrochloride is a potent, selective, and orally bioactive EGFR tyrosine kinase inhibitor with IC50 of 0.7 nM. | [in vivo]
PKI-166 hydrochloride (100 mg/kg; po; daily; for 29 days) inhibits of pancreatic cancer growth.
| Animal Model: < /td> | Male athymic nude mice with L3.6pl cells xenograft (8-12 weeks) | | Dosage: < /td> | 100 mg/kg | | Administration: | Oral administration; daily; for 29 days | | Result: | Significantly decreased median tumor volume. | | [target]
IC50: 0.7 nM (EGFR tyrosine kinase) | [storage]
Store at -20°C | [References]
[1] Bruns CJ, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000 Jun 1;60(11):2926-35. PMID:10850439 |
|
|